Anticancer Potential of ACEIs/ARBs Administration in Colorectal Cancer


Cite item

Full Text

Abstract

Background:Colorectal cancer (CC) is the fourth most common type of cancer that causes illness and death. Medicines like ACE inhibitors and ARBs, usually used for heart problems, have shown they might help with the growth and development of CC.

Introduction:An analysis of ACE inhibitors and colon cancer is conducted in this comprehensive review. The main goal is to see how ACEIs/ARBs affect the chances of getting cancer and dying in patients with CC.

Methods:A systematic literature search was conducted to identify relevant studies. Inclusion criteria encompassed studies that evaluated the use of ACEIs/ARBs in patients with CC and reported outcomes related to new cancer incidence and mortality. Data from selected studies were extracted and analyzed using appropriate statistical methods.

Results:The study showed that fewer cancer cases occurred in patients who took ACEIs/ARBs compared to those who did not (RR 0.962, 95% CI 0.934-0.991, p = 0.010). Furthermore, patients with CC who utilized ACEIs/ARBs exhibited a decreased mortality rate compared to non-users (HR 0.833, 95% CI 0.640-1.085, p = 0.175).

Conclusion:This review suggests that using ACEIs/ARBs medicine could help people with CC live longer and lower their chances of dying. These results highlight the potential benefits of utilizing ACE inhibitors in the management of CC, warranting further investigation and consideration in clinical practice.

About the authors

Xin Wang

Department of Cardiology, The Second Affiliated Hospital of Zhengzhou University

Email: info@benthamscience.net

Haiyun Jing

Department of Cardiology, Zhengzhou Central Hospital

Author for correspondence.
Email: info@benthamscience.net

References

  1. Asgharzadeh, F.; Mostafapour, A.; Ebrahimi, S.; Amerizadeh, F.; Sabbaghzadeh, R.; Hassanian, S.M.; Fakhraei, M.; Farshbaf, A.; Ferns, G.A.; Giovannetti, E.; Avan, A.; Khazaei, M. Inhibition of angiotensin pathway via valsartan reduces tumor growth in models of colorectal cancer. Toxicol. Appl. Pharmacol., 2022, 440, 115951. doi: 10.1016/j.taap.2022.115951 PMID: 35235860
  2. Asgharzadeh, F.; Naghibzadeh, N.; Hashemzehi, M.; Mostafapour, A.; Hassanian, S.M.; Avan, A.; Khazaei, M. Angiotensin II receptor antagonist, valsartan, has beneficial effect in lung metastasis of colorectal cancer treated with fluorouracil. J. Gastrointest. Cancer, 2023, 54(1), 126-134. doi: 10.1007/s12029-021-00717-8 PMID: 35083728
  3. Hashemzehi, M.; Rahmani, F.; Khoshakhlagh, M.; Avan, A.; Asgharzadeh, F.; Barneh, F.; Moradi-Marjaneh, R.; Soleimani, A.; Fiuji, H.; Ferns, G.A.; Ryzhikov, M.; Jafari, M.; Khazaei, M.; Hassanian, S.M. Angiotensin receptor blocker Losartan inhibits tumor growth of colorectal cancer. EXCLI J., 2021, 20, 506-521. PMID: 33883980
  4. Tabatabai, E.; Khazaei, M.; Asgharzadeh, F.; Nazari, S.E.; Shakour, N.; Fiuji, H.; Ziaeemehr, A.; Mostafapour, A.; Parizadeh, M.R.; Nouri, M.; Hassanian, S.M.; Hadizadeh, F.; Ferns, G.A.; Rahmati, M.; Rahmani, F.; Avan, A. Inhibition of angiotensin II type 1 receptor by candesartan reduces tumor growth and ameliorates fibrosis in colorectal cancer. EXCLI J., 2021, 20, 863-878. PMID: 34121975
  5. Asgharzadeh, F.; Jafarzadeh-Esfehani, R.; Hassanian, S.M.; Ferns, G.A.; Avan, A.; Khazaei, M. Renin-angiotensin system inhibitors and development of hepatocellular carcinoma: A systematic review and meta-analysis. Curr. Pharm. Des., 2020, 26(39), 5079-5085. doi: 10.2174/1381612826666200713165018 PMID: 32660400
  6. Telles-Langdon, S.M.; Arya, V.; Jassal, D.S. Renin angiotensin system (RAS): The common thread between cancer and heart failure, in the renin angiotensin system in cancer, lung. In: Liver and Infectious Diseases; Springer, 2023; pp. 429-449.
  7. Mostafapour A.; Asgharzadeh F.; Yaghoubi A.; Eskandari M.; Elnaz Nazari S.; Naghibzadeh N.; Baharara J.; Avan A.; Mahdi Hassanian S.; Hajzadeh M. Khazaei M.Angiotensin-converting enzyme inhibitor, enalapril, inhibits tumor growth and potentiates the antitumor efficacy of 5-fu in colorectal cancer. 2022, 9, e2314. doi: 10.32113/wcrj_20225_2314
  8. Saeedi, N.; Mansoori, S.; Asgharzadeh, F.; Soleimani, A.; Mollazadeh, S.; Hassanian, S.M. Influence of renin-angiotensin system inhibitors on the treatment of metastatic renal cancer. Curr. Pharm. Des., 2023, 29(18), 1459-1465. doi: 10.2174/1381612829666230524152108 PMID: 37226780
  9. Salim, H.; Jones, A.M. Angiotensin II receptor blockers (ARBs) and manufacturing contamination: A retrospective National Register Study into suspected associated adverse drug reactions. Br. J. Clin. Pharmacol., 2022, 88(11), 4812-4827. doi: 10.1111/bcp.15411 PMID: 35585835
  10. Asgharzadeh, F.; Hassanian, S.M.; Ferns, G.A.; Khazaei, M.; Hasanzadeh, M. The therapeutic potential of angiotensin-converting enzyme and angiotensin receptor inhibitors in the treatment of colorectal cancer: Rational strategies and recent progress. Curr. Pharm. Des., 2019, 24(39), 4652-4658. doi: 10.2174/1381612825666190111145140 PMID: 30636592
  11. Wu, J.; Wang, M.; Guo, M.; Du, X. Y.; Tan, X. Z.; Teng, F. Y.; Xu, Y. Angiotensin receptor blocker is associated with a lower fracture risk: An updated systematic review and meta-analysis. Int. J. Clin. Pract., 2022. Wu, J.; Wang, M.; Guo, M.; Du, X. Y.; Tan, X. Z., Teng, F. Y., & Xu, Y. (2022). Angiotensin receptor blocker is associated with a lower fracture risk: An updated systematic review and meta-analysis. Int. J. Clin. Pract., 2022, 2022, 7581110. doi: 10.1155/2022/7581110
  12. Santiago, T.C.; Parra, L.; Nani, J.V.; Fidalgo, T.M.; Bradshaw, N.J.; Hayashi, M.A.F. Angiotensin-converting enzymes as druggable features of psychiatric and neurodegenerative disorders. J. Neurochem., 2023, 166(2), 138-155. doi: 10.1111/jnc.15806 PMID: 36908214
  13. Koh, Sabrina P.; Ethan J.; Kilmister, Agadha C.; Wickremesekera.; Matthew J.; Munro.; Clint Gray.; and Swee T.; Tan. "The Renin-Angiotensin System and Cancer." In The Renin Angiotensin System in Cancer, Lung, Liver and Infectious Diseases. Springer, 2023, 277-339. doi: 10.1007/978-3-031-23621-1_15
  14. Singh, A.; Bedi, P.M.S. Renin angiotensin system activity in different cancers: Mechanistic insight and preclinical studies. In: The Renin Angiotensin System in Cancer, Lung, Liver and Infectious Diseases; Springer, 2023; pp. 379-394. doi: 10.1007/978-3-031-23621-1_18
  15. Balkwill, F.; Mantovani, A. Inflammation and cancer: back to Virchow? Lancet, 2001, 357(9255), 539-545. doi: 10.1016/S0140-6736(00)04046-0 PMID: 11229684
  16. Valle-Mendiola, A.; Gutiérrez-Hoya, A.; Soto-Cruz, I. JAK/STAT Signaling and cervical cancer: From the cell surface to the nucleus. Genes, 2023, 14(6), 1141. doi: 10.3390/genes14061141 PMID: 37372319
  17. Su, J. Renin-Angiotensin System and Cancer: From Laboratory to Clinics; The Renin Angiotensin System in Cancer, Lung, Liver and Infectious Diseases, 2023, pp. 341-363.
  18. Ivković, I.; Limani, Z.; Jakovčević, A.; Huić, D.; Prgomet, D. Role of matrix metalloproteinases and their inhibitors in locally invasive papillary thyroid cancer. Biomedicines, 2022, 10(12), 3178. doi: 10.3390/biomedicines10123178 PMID: 36551933
  19. Pramanik, K.K.; Mishra, R. ERK-mediated upregulation of matrix metalloproteinase-2 promotes the invasiveness in human oral squamous cell carcinoma (OSCC). Exp. Cell Res., 2022, 411(1), 112984. doi: 10.1016/j.yexcr.2021.112984 PMID: 34951997
  20. Rao, Q.; Yu, H.; Li, R.; He, B.; Wang, Y.; Guo, X.; Zhao, G.; Wu, F. Dihydroartemisinin inhibits angiogenesis in breast cancer via regulating VEGF and MMP-2/-9. Fundam. Clin. Pharmacol., 2023, fcp.12941. doi: 10.1111/fcp.12941 PMID: 37490927
  21. Pinheiro, L.; Perdomo-Pantoja, A.; Casaos, J.; Huq, S.; Paldor, I.; Vigilar, V.; Mangraviti, A.; Wang, Y.; Witham, T.F.; Brem, H.; Tyler, B. Captopril inhibits Matrix Metalloproteinase-2 and extends survival as a temozolomide adjuvant in an intracranial gliosarcoma model. Clin. Neurol. Neurosurg., 2021, 207, 106771. doi: 10.1016/j.clineuro.2021.106771 PMID: 34198223
  22. Shebl, R.I. Anticancer potential of captopril and botulinum toxin type-A and associated p53 gene apototic stimulating activity. Iran. J. Pharm. Res., 2019, 18(4), 1967-1977. PMID: 32184862
  23. Caimi, G.; Hopps, E.; Montana, M.; Urso, C.; Carollo, C.; Canino, B.; Lo Presti, R. The function of matrix metalloproteinase-9 (MMP-9) and its tissue inhibitor (TIMP-1) in several clinical conditions: Results and analysis of our survey. Clin. Hemorheol. Microcirc., 2021, 78(4), 401-416. doi: 10.3233/CH-201094 PMID: 33814420
  24. Das, S.; Amin, S.A.; Jha, T. Inhibitors of gelatinases (MMP-2 and MMP-9) for the management of hematological malignancies. Eur. J. Med. Chem., 2021, 223, 113623. doi: 10.1016/j.ejmech.2021.113623 PMID: 34157437
  25. Afsar, B.; Afsar, R.E.; Ertuglu, L.A.; Kuwabara, M.; Ortiz, A.; Covic, A.; Kanbay, M. Renin-angiotensin system and cancer: epidemiology, cell signaling, genetics and epigenetics. Clin. Transl. Oncol., 2021, 23(4), 682-696. doi: 10.1007/s12094-020-02488-3 PMID: 32930920
  26. Hashemzehi, M.; Beheshti, F.; Hassanian, S.M.; Ferns, G.A.; Khazaei, M.; Avan, A. Therapeutic potential of renin angiotensin system inhibitors in cancer cells metastasis. Pathol. Res. Pract., 2020, 216(7), 153010. doi: 10.1016/j.prp.2020.153010 PMID: 32534713
  27. Erdat, E.C.; Koksoy, E.B.; Utkan, G. Enhancing the Anti-angiogenic Effect of Bevacizumab with ACE Inhibition on mCRC. J. Gastrointest. Cancer, 2022, 1-6. doi: 10.1007/s12029-022-00890-4 PMID: 36401084
  28. Lu, H.; Yuan, P.; Ma, X.; Jiang, X.; Liu, S.; Ma, C.; Philipsen, S.; Zhang, Q.; Yang, J.; Xu, F.; Zhang, C.; Zhang, Y.; Zhang, W. Angiotensin-converting enzyme inhibitor promotes angiogenesis through Sp1/Sp3-mediated inhibition of notch signaling in male mice. Nat. Comm., 2023, 14, 731. doi: 10.1038/s41467-023-36409-z
  29. Noureddin, M.; Abdelmalek, M.F. ACE inhibitors: The secret to prevent cirrhosis complications and HCC in NAFLD? Hepatology, 2022, 76(2), 295-297. doi: 10.1002/hep.32399 PMID: 35124826
  30. Dierssen-Sotos, T.; Gómez-Acebo, I.; Palazuelos C.; Rodriguez-Moranta, F.; Pérez-Gómez, B.; Fernández Vazquez, J.P.; Amiano P. Relationship between drugs affecting the renin-angiotensin system and colorectal cancer. The MCC-Spain study., 2017, 99, 178-184. doi: 10.1016/j.ypmed.2017.01.011
  31. Tascilar, K.; Azoulay, L.; Dell’Aniello, S.; Bartels, D.B.; Suissa, S. The use of telmisartan and the incidence of cancer. Am. J. Hypertens., 2016, 29(12), 1358-1365. doi: 10.1093/ajh/hpw095
  32. Osumi, H.; Matsusaka, S.; Wakatsuki, T.; Suenaga, M.; Shinozaki, E.; Mizunuma, N. Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients. Mol. Clin. Oncol., 2015, 6(3), 1295-1300. doi: 10.3892/mco.2015.630
  33. Kedika, R.M.D.; Patel, M.M.D.; Sahdala, P.H.N.M.D.; Mahgoub, A.M.D.; Cipher, D.; Siddiqui, A.A. Long-term use of angiotensin converting enzyme inhibitors is associated with decreased incidence of advanced adenomatous colon. J. Polyps., 2011, 45(2), e12-e16. doi: 10.1097/MCG.0b013e3181ea1044
  34. Engineer, D.R.; Burney, B.O.; Hayes, T.G.; Garcia, J.M. Exposure to ACEI/ARB and β-blockers is associated with improved survival and decreased tumor progression and hospitalizations in patients with advanced colon cancer. Trans. Oncol., 2013, 6(5), 539-545. doi: 10.1593/tlo.13346 PMID: 24151534
  35. Van Der Knaap, R. Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: The rotterdam study. 2008, 112(4), 748-757. doi: 10.1002/cncr.23215 PMID: 18181094
  36. Wang, K.L.; Liu, C.J.; Chao, T.F.; Huang, C.M.; Wu, C.; Chen, T.J.; Chiang, E.N. Long-term use of angiotensin receptor blockers and risk of cancer: A population-based cohort analysis. 2013, 167(5), 2126-2166. doi: 10.1016/j.ijcard.2012.05.096
  37. Hallas, J.; Rene, C.; Morten, A.; Søren, F.; Lars, B. Long term use of drugs affecting the renin-angiotensin system and the risk of cancer: A population-based case-control study. Br. J. Clin. Pharmacol, 2012, 74(1), 180-188. doi: 10.1111/j.1365-2125.2012.04170.x
  38. Mansouri, D.; McMillan, D.C.; Roxburgh, C.S.D.; Crighton, E.M.; Horgan, P.G. The impact of aspirin, statins and ACE-inhibitors on the presentation of colorectal neoplasia in a colorectal cancer screening programme. Br. J. Cancer., 2013, 109(1), 249-256. doi: 10.1038/bjc.2013.292
  39. Cardwell, C.R.; Úna, C.; Menamin, Mc.; Blánaid, M.; Hicks, C.H.; Marie, M.; Cantwell; Liam, J. Drugs affecting the renin-angiotensin system and survival from cancer: A population-based study of breast, colorectal and prostate cancer patient cohorts. BMC Medicine, 2014, 12(1), 1-15. doi: 10.1186/1741-7015-12-28
  40. Makar, G.A.; Holmes, J.H.; Yang, Y.X. Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk. J. Natl. Cancer Inst., 2014, 106(2), djt374. doi: 10.1093/jnci/djt374
  41. Boudreau, D.M.; Koehler, E.; Rulyak, S.J.; Heckbert, S.; Hindorff, R.; Thompson, M.; Mandelson, M. Cardiovascular medication use and risk for colorectal cancer. 2008, 17(11), 3076-3080. doi: 10.1158/1055-9965.EPI-08-0095
  42. Azoulay, L.; Leone, T.L.; Assimes, H.Y.; Bonnet, D.; Bartels, E.L.; Schiffrin, S.S. Long-term use of angiotensin receptor blockers and the risk of cancer. PloS One, 2012, 7(12), e50893. doi: 10.1371/journal.pone.0050893
  43. Holmes, S.; Griffith, E.J.; Musto, G.; Minuk, G.Y. Antihypertensive medications and survival in patients with cancer: A population-based retrospective cohort study. Cancer Epidemiol., 2013, 37(6), 881-885. doi: 10.1016/j.canep.2013.09.001 PMID: 24075077
  44. Assimes, T.L.; Elstein, E.; Langleben, A.; Suissa, S. Long-term use of antihypertensive drugs and risk of cancer. Pharmacoepidemiol. Drug Saf., 2008, 17(11), 1039-1049. doi: 10.1002/pds.1656 PMID: 18780400
  45. McNutt, L.A.; Hafner, J-P.; Xue, X. Correcting the odds ratio in cohort studies of common outcomes. JAMA, 1999, 282(6), 529-529. doi: 10.1001/jama.282.6.529 PMID: 10450713
  46. Engineer, D.R.; Burney, B.O.; Hayes, T.G.; Garcia, J.M. Exposure to ACEI/ARB and β-Blockers is associated with improved survival and decreased tumor progression and hospitalizations in patients with advanced colon cancer. Transl. Oncol., 2013, 6(5), 539-545. doi: 10.1593/tlo.13346 PMID: 24151534
  47. Terrin, N.; Schmid, C.H.; Lau, J.; Olkin, I. Adjusting for publication bias in the presence of heterogeneity. Stat. Med., 2003, 22(13), 2113-2126. doi: 10.1002/sim.1461 PMID: 12820277
  48. Abali, H.; Güllü, I.H.; Engin, H.; Haznedaroğlu, I.C.; Erman, M.; Tekuzman, G. Old antihypertensives as novel antineoplastics: Angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists. Med. Hypotheses, 2002, 59(3), 344-348. doi: 10.1016/S0306-9877(02)00185-8 PMID: 12208167
  49. Almutlaq, M.; Alamro, A.A.; Alamri, H.S.; Alghamdi, A.A.; Barhoumi, T. The effect of local renin angiotensin system in the common types of cancer. Front. Endocrinol., 2021, 12, 736361. doi: 10.3389/fendo.2021.736361 PMID: 34539580
  50. Perini, M.V.; Dmello, R.S.; Nero, T.L.; Chand, A.L. Evaluating the benefits of renin-angiotensin system inhibitors as cancer treatments. Pharmacol. Ther., 2020, 211, 107527. doi: 10.1016/j.pharmthera.2020.107527 PMID: 32173557
  51. Zhou, Q.; Chen, D.S.; Xin, L.; Zhou, L.Q.; Zhang, H.T.; Liu, L.; Yuan, Y.W.; Li, S.H. The renin–angiotensin system blockers and survival in digestive system malignancies. Medicine (Baltimore), 2020, 99(7), e19075. doi: 10.1097/MD.0000000000019075 PMID: 32049809
  52. Li, Y.; Yan, Z.; Chaudhry, K.; Kazlauskas, A. The renin-angiotensin-aldosterone system (RAAS) is one of the effectors by which vascular endothelial growth factor (VEGF)/anti-VEGF controls the endothelial cell barrier. Am. J. Pathol., 2020, 190(9), 1971-1981. doi: 10.1016/j.ajpath.2020.06.004 PMID: 32590003
  53. Zhang, H.F.; Gao, X.; Wang, X.; Chen, X.; Huang, Y.; Wang, L.; Xu, Z.W. The mechanisms of renin–angiotensin system in hepatocellular carcinoma: From the perspective of liver fibrosis, HCC cell proliferation, metastasis and angiogenesis, and corresponding protection measures. Biomed. Pharmacother., 2021, 141, 111868. doi: 10.1016/j.biopha.2021.111868 PMID: 34328104
  54. Ziaja, M.; Urbanek, K.A.; Kowalska, K.; Piastowska-Ciesielska, A.W. Angiotensin II and angiotensin receptors 1 and 2—multifunctional system in cells biology, what do we know? Cells, 2021, 10(2), 381. doi: 10.3390/cells10020381 PMID: 33673178
  55. Pillai U, J.; Ray, A.; Maan, M.; Dutta, M. Repurposing drugs targeting metabolic diseases for cancer therapeutics. Drug Discov. Today, 2023, 28(9), 103684. doi: 10.1016/j.drudis.2023.103684 PMID: 37379903
  56. Morris, Z.S.; Saha, S.; Magnuson, W.J.; Morris, B.A.; Borkenhagen, J.F.; Ching, A.; Hirose, G.; McMurry, V.; Francis, D.M.; Harari, P.M.; Chappell, R.; Tsuji, S.; Ritter, M.A. Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. Cancer, 2016, 122(16), 2487-2495. doi: 10.1002/cncr.30079 PMID: 27203227
  57. Dai, Y.N.; Wang, J.H.; Zhu, J.Z.; Lin, J.Q.; Yu, C.H.; Li, Y.M. Angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy and colorectal cancer: A systematic review and meta-analysis. Cancer Causes Control, 2015, 26(9), 1245-1255. doi: 10.1007/s10552-015-0617-1 PMID: 26081426
  58. Kumekawa, Y. ACEIs/ARBs to improve survival in advanced gastric cancer patients receiving S-1 plus cisplatin. J. Clinical Oncol., 2015, 33(3), 174. doi: 10.1200/jco.2015.33.3_suppl.174

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers